BioCentury
ARTICLE | Clinical News

Regeneron, Sanofi planning dupilumab Phase III in asthma

November 12, 2014 2:16 AM UTC

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and partner Sanofi (Euronext:SAN; NYSE:SNY) said they plan to run a Phase III trial of dupilumab to treat adults with uncontrolled moderate-to-severe asthma after interim Phase IIb data showed the three highest of four antibody dose regimens met the primary endpoint in patients with high eosinophils.

Regeneron spokesperson Alexandra Bowie would not disclose when the companies plan to begin the trial. ...